Weight loss injection on the NHS: understanding your options

What the NHS currently prescribes for weight loss, and where

Two GLP-1 medicines are licensed in the UK for weight management and available, in principle, through the NHS. Semaglutide, sold as Wegovy, is a once-weekly injection that NICE recommended for NHS use back in 2023 under its TA875 guidance. Tirzepatide, sold as Mounjaro, followed with a NICE recommendation in December 2024 (TA1026). Both are genuinely effective (clinical trials reported average weight reductions of around 15% for semaglutide at 2.4mg and around 20–21% for tirzepatide at its highest dose) but the NHS does not simply hand them out on request.

Wegovy is routed through specialist weight management services, which carry long waiting lists in most areas. Tirzepatide is being introduced into GP practices, but only those that have signed up to the new contract and can offer the required dietary and lifestyle wraparound support. Many practices haven't, and availability varies significantly depending on where you live. The rollout is phased, not a blanket national launch.

It's also worth knowing that Ozempic (the same semaglutide molecule) is licensed for type 2 diabetes management, not for weight loss. The NHS does not prescribe it as a weight loss injection, and requesting it for that purpose will be declined.

Who actually qualifies for a weight loss injection on the NHS

For tirzepatide, NHS England has set out a phased eligibility schedule tied to BMI and the number of specific health conditions a person has. From June 2025, the first cohort to qualify was adults with a BMI of 40 or above plus at least four of five named conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, or type 2 diabetes. The criteria broaden over time, with a second cohort (BMI 35–39.9, same four conditions) activated in June 2026, and further groups expected from around March 2027.

For semaglutide under TA875, the NHS requires use within a specialist weight management service, a BMI of at least 35, and at least one weight-related comorbidity. Treatment is authorised for a maximum of two years.

Across both medicines, BMI thresholds are reduced by 2.5 kg/m² for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds. And in every case, meeting the number on paper isn't enough, each patient's full clinical picture is assessed. Scotland, Wales and Northern Ireland operate under different criteria and commissioning arrangements.

If you're uncertain where you stand, the eligibility question is worth looking at in detail rather than assuming you do or don't qualify.

Why many people who want a weight loss injection end up going private

The most common reason isn't that people fail to meet BMI criteria. It's that they don't have enough qualifying conditions, their GP practice isn't yet participating in the tirzepatide scheme, or the wait for a specialist service is measured in months rather than weeks. There's also a practical gap: the NHS phased rollout is designed to reach millions of people over several years, not everyone at once.

A regulated private pharmacy fills that space legally. The private licensed eligibility criteria align with the medicine's licence: a BMI of 30 or above, or 27 or above with at least one weight-related condition such as prediabetes, hypertension, high cholesterol or obstructive sleep apnoea. No GP referral is needed. At nume, a GPhC-registered Independent Prescriber reads your consultation the same day, a real clinician, not automated software. If treatment is approved and your order is placed before midday, it's dispatched the same day.

What arrives is straightforward: a DPD tracking notification on your phone, then a plain, unbranded box at your door the next working day. Inside is the pen itself, the Patient Information Leaflet, and everything you need to get started. The cost question is a fair one to ask at this stage, and worth reading before deciding.

The practical decision: NHS or private prescription

This comes down to three things: whether you meet NHS criteria right now, how long you're prepared to wait, and what level of clinical oversight you want throughout. The NHS route costs you nothing if you qualify, but the waiting and the eligibility conditions are real constraints. A private prescription through a pharmacy registered with the GPhC gives you a faster, clinically supervised alternative, but it comes at a cost, and that cost should be all-in, not a headline pen price that excludes the consultation, prescription review, and aftercare.

For a prescription medicine like this, the question of where to get it matters as much as whether to get it. The MHRA has issued multiple warnings about counterfeit weight loss pens sold online, including fake tirzepatide products. Any seller offering these medicines without a prior clinical assessment is operating outside the law. You can verify any online pharmacy on the GPhC register, it takes about thirty seconds and is worth doing.

If you'd like to know whether you're eligible for a private prescription, check your eligibility with our prescribers. There's no cost to the consultation and no obligation to proceed.